Introduction doctor in Naples (5) . This was the first use of animals for large-scale vaccine production. Thereafter, numerous vaccines for both human and animal use were produced in animals. In 1796, Edward Jenner conducted the first smallpox vaccination using material obtained from a lesion on a cow suffering from cowpox. Subsequently, the vaccine was maintained by ann-to-arm passage until the mid-1840s, when the technique for the production of smallpox vaccine on the skin of calves or sheep was developed by Negri, a medical
The next breakthrough in technology came in the mid-1950s, when chicken embryos and tissue culture cells were adapted for the production of vaccines, Flowever, the basic concept exist. This is a relatively easy task, since the virion RNA produced from the modified DNA copy of the genome of positive-strand virus is infectious when injected into susceptible cells. In the case of negative-strand viruses, the task is more difficult since the genome RNA is not infectious. However, recent advances in molecular techniques have enabled this difficulty to be overcome, and it is now possible to produce infectious virus from DNA copies of RNA viruses, such as rabies, Sendai virus, measles, rinderpest and respiratory syncytial virus (13) . Extra reading frames have been incorporated into these genomes and it is now possible to produce genetically defined and marked vaccines and to use these viruses as vectors for other immunogenic proteins.
In 1990, a unique approach to vaccination was reported, i.e. the use of naked DNA encoding immunogenic proteins as vaccines. Over the past seven years, DNA vaccines have been produced for a variety of diseases and tested in the laboratory with considerable success. These advances in molecular technology have created new opportunities to produce safer, genetically defined vaccines for both human and veterinary use. In this paper the present situation regarding the development and testing of virus vector vaccines and DNA vaccines, as well as the potential usefulness of the rescue system of negative-strand RNA viruses, will be reviewed.
Vector vaccines based on deoxyribonucleic acid viruses
Following the demonstration in 1982 that foreign antigens could be expressed using vaccinia virus (26, 35) , many attempts have been made to develop a variety of new vaccines using vaccinia virus as a vector, especially in the field of veterinary medicine. Table I summarises the examples of vector vaccines developed for veterinary use.
At first, the smallpox vaccine, which was used in the campaign for the global eradication of smallpox, was used as the vector. However, the low morbidity and mortality rate associated with smallpox vaccination was considered to pose too great a risk to make such recombinant vaccines acceptable for widespread human use. This is particularly the case in areas of the world where large sections of the population are immunocompromised due to high rates of human immunodeficiency virus (HIV) infection. More attenuated strains of the vaccine were investigated and, more recently, vaccinia virus attenuated by genetic manipulation was constructed, in the search for suitable vectors for the expression of immunogenic foreign proteins for veterinary and human use. The concept of vector attenuation has been developed still further by the use of poxviruses that do not replicate in the target host, i.e. avipox viruses in mammals. Other large DNA viruses, such as the herpesviruses, have been used as vectors for particular animal species. These include Aujeszky's disease (pseudorabies) virus for use in pigs, herpesvirus of turkeys and feline and canine herpesviruses.
Adenovirus, a smaller DNA virus, has also been used as an expression vector. However, due to technical difficulties, particularly the tight constraints on the size of DNA insert that can be accommodated in the genome, construction of recombinant adenoviruses has been limited. Adenoviruses expressing foreign proteins are considered suitable as vectors in 'gene therapy' and this has led to technical improvements in the vectors now available. In the future, adenovirusrecombinant vaccines may be more widely tested, particularly as they have the potential to elicit a strong mucosal immune response.
Recombinant vaccines based on mammalian poxvirus vectors
Although the pioneering work on recombinant vaccine production was conducted using vaccinia virus, the only vaccinia-based recombinant virus licensed as a veterinary vaccine is the rabies-recombinant vaccine. This vaccine is used for the oral vaccination against rabies of foxes in Europe and raccoons and striped skunks in North America; these species being the most important natural reservoirs of rabies greater than one year, were confirmed (22) . This vaccine (LC16mO) was also shown to be highly heat-stable when lyophilised -a stability comparable to that of the original smallpox vaccine -and is now ready for testing under field conditions. The RRV (Wyeth) has similarly been shown to protect cattle from challenge with virulent rinderpest virus in preliminary short-term trials (19) . The RRV (capripox) has the added advantages that it can be used to protect cattle against both rinderpest and lumpy skin disease and is non-pathogenic for humans, making it extremely safe to handle. One disadvantage associated with the RRV (capripox)
vaccine is the interference with the efficacy of the vaccine caused by pre-existing anti-capripox antibodies, a factor which was not a problem in the case of RRV (LC16mO) (32, 56) .
Swinepox, another mammalian pox virus, has been considered as a vector for use in pigs. The disease caused by swinepox virus in pigs is relatively benign, its natural host range is restricted to this species and it is found worldwide.
Based on these ideal vector characteristics, a recombinant During the smallpox eradication campaign, four highly attenuated strains of smallpox virus were developed for use as vaccines. These were the LC16mO and LC16m8 strains (21), the modified Ankara (MVA) strain (29) and the CV-1 strain (24).
Further attenuation of the vaccinia virus vector
Both LC16mO and LC16m8 were derived from the Lister strain by selecting a temperature-sensitive mutant, which was then grown in rabbit kidney (RK) 13 cells. These strains were
shown to be attenuated in human trials but only the latter was licensed as an attenuated smallpox vaccine.
The attenuation of the MVA strain was also confirmed in large-scale human trials. Since this virus was passaged over 570 times in chicken embryo fibroblasts, it does not productively infect mammalian cells and must be grown in avian cells (42) , making it an ideal vaccinia strain for use as a recombinant vaccine vector.
The CV-1 strain was passaged in chicken embryo organ culture and on the chorioallantoic membranes of chicken embryos more than 70 times in total. In a comparative study of subcutaneous inoculation in humans, however, this virus was found to be less likely to induce antibody, compared with the Lister and other strains (12) . As a result of the high immunogenicity of the LC16mO strain in rabbits and cattle, the recombinant rinderpest vaccine was developed using this vaccinia strain as the vector, and its efficacy and safety were confirmed, as described in the previous section (see ' Recombinant vaccines based on mammalian poxvirus vectors', above). The MVA strain was used to make a recombinant influenza vaccine expressing the haemagglutinin and nucleoprotein genes of influenza virus, and protective immunity was demonstrated in mice (45) .
Attenuation of a conventional smallpox vaccine (Copenhagen strain) has been attempted by deleting virulence-associated and host-range genes. In total, 18 genes were serially deleted from the genome to produce a virus which was designated the NYVAC strain. The attenuated nature of the resultant virus was demonstrated by the following criteria: However, possible adverse reactions in humans have not yet been examined. A recombinant Aujeszky's disease vaccine expressing Aujeszky's disease virus glycoproteins was developed using this strain of vaccinia virus which, in contrast to the swinepox-recombinant mentioned in the previous section (see ' Recombinant vaccines based on mammalian poxvirus vectors', above) (50) , gave significant protection when tested in pigs (10).
Recombinant vaccines based on avipoxvirus vectors
Live attenuated fowlpox vaccine has been widely used to produce recombinant vaccines for chickens. 
Recombinant vaccines based on herpesvirus vectors
Herpesviruses are also considered to be useful vectors for 
Recombinant vaccines based on adenovirus vectors
Adenoviruses 
Recombinant vaccines based on positive-strand ribonucleic acid viruses
In the case of positive-strand RNA viruses, advances in molecular techniques have enabled scientists to modify individual genes, as in the case of DNA viruses. Moreover, because of their small size, whole virus genomes can be copied into DNA and manipulated at will. This not only allows known attenuating mutations to be incorporated into the genome to produce genetically defined and marked vaccines but also means that extra coding sequences for foreign proteins can be incorporated to produce vector vaccines. The RNA transcribed from a DNA clone in vitro is infectious if injected into a cell. To obtain infectious virus, injecting the DNA is sufficient since the RNA can be transcribed from this DNA in the cell, if it has a suitable promoter (38) . This approach has been applied successfully to many plant and animal viruses (8) .
Some unusual approaches to vaccination have been attempted using Picornaviridae, small positive-strand RNA viruses. The size and very ordered structure of these viruses do not allow insertion of significant amounts of foreign genetic material, but small pieces of DNA coding for known protective epitopes can be inserted in particular regions of the capsid proteins. Poliovirus is one of the safest and most widely used of the human vaccines, and DNA copies of its genome can be used to obtain live virus from transfected cells. In addition, the antigenic regions on the virus capsid protein have been identified and these have been replaced by protective epitopes from other viruses, most notably foot and mouth disease virus (FMDV) (25) . The antigenic sites on FMDV capsid proteins have been extensively studied and mapped very accurately and, since the two viruses are similar in structure, it is possible to exchange antigenic sites without fatally disrupting the virus. These chimeric viruses have been shown to elicit immune responses specific to FMDV in guinea-pigs but have not been tested in the target animals for the vaccine: cattle, pigs, sheep and goats.
Other epitopes derived from HIV have also been inserted into the poliovirus genome. Plant picomaviruses, e.g. cowpea mosaic virus, have also had FMDV-protective epitopes inserted into their capsid proteins, with the hope that infecting plants with these virus chimeras will eventually lead to oral vaccination of the animals which eat them (37) . The same authors also inserted epitopes from human rhinovirus 14 (HRV-14) and HIV into cowpea mosaic virus but only the HRV-14 chimera was tested for immunogenicity. There is no safely attenuated FMDV vaccine, and the protective response to purified inactivated virus antigen preparations is very short-lived. Vaccination, which is very costly, must be conducted every six months if it is to be effective, and so any improvement on the existing inactivated FMDV vaccines would be of great economic benefit. Such colourful approaches to vaccination may not, in the end, lead to useful vaccines, but they will provide insights into the immune responses to protective epitopes expressed in unusual ways.
Recombinant vaccines based on negative-strand ribonucleic acid viruses The great advantage of such systems is the generally very long-lasting immunity generated following infection or vaccination with paramyxoviruses (e.g. measles and rinderpest viruses induce life-long immunity), and if such long-lasting immunity could be transferred to other diseases, such as FMD, the advantages would be considerable. A synthetic gene incorporating B-and T-cell stimulating epitopes from FMDV has been successfully inserted and expressed in the rinderpest virus genome and the protective immunity generated against FMDV is now being studied (2) . The other advantage of this system is the ability to place marker genes into the genomes of paramyxovirus vaccine strains, with the consequent ability to distinguish vaccination from natural infection easily, using serological techniques (see 'Role of recombinant vaccines in vaccination campaigns', below).
Deoxyribonucleic acid vaccines
The idea of using naked DNA as a vaccine was proposed by 
Advantages of deoxyribonucleic acid vaccines
The production of DNA vaccines is based on the growth of bacterial plasmid DNA, so that large-scale production at high purity can be conducted inexpensively. 
Deoxyribonucleic acid vaccines for veterinary use
Owing to the advantages of DNA vaccines detailed above, they have been widely studied as candidate vaccines for both humans and animals and are considered to hold great potential for future vaccine development. Table II 
Problems which remain to be solved
Although the effectiveness of DNA vaccine has been shown for a variety of viruses and other micro-organisms, some basic questions concerning the nature of the protection mechanisms remain unanswered. The DNA introduced into mouse muscle cells has been shown to persist episomally for up to 18 months. It is speculated that the DNA is continuously expressed and the antigen is processed for MHC class I presentation in the cytoplasm of muscle cells, but the type of cell in the muscle which presents the antigen for CTL induction is not known. Plasmid vectors expressing large amounts of gene product do not necessarily induce immune response to the encoded antigen. Short immunostimulatory DNA sequences, which contain a CpG dinucleotide in a particular base context, have been identified (41) . These induce pro-inflammatory cytokines and improve the immune response to the plasmid-expressed foreign DNA.
Mechanisms to increase the immunogenicity of DNA vaccines are an important area for future study. A better understanding of the mechanisms that induce CTL activity will enhance the ability to design more effective conventional and DNA vaccines in future. As DNA vaccines rely on very strong viral promoters to drive expression of the foreign genes, accidental integration of DNA into the genome of those vaccinated is of major concern when contemplating use of these vaccines in humans. This kind of risk, however, may be trivial in most farm animals with short lifespans, but may have to be considered when using DNA vaccines for animals with long lifespans.
Role of recombinant vaccines in vaccination campaigns
In 
Mots-clés
Adénovirus vecteur -Herpèsvirus vecteur -Poxvirus vecteur -Système de récupération -Vaccin à acide désoxyribonucléique -Vaccin à vecteur -Vaccin recombinant.
• Nuevas soluciones para el desarrollo de vacunas víricas de uso veterinario 
Palabras clave
Sistema de rescate -Vacuna de ácido desoxirribonucleico -Vacuna recombinanteVacuna vehiculada por un vector -Vector adenovirus -Vector herpesvirus -Vector poxvirus.
